A recent retrospective study of 6290 NSCLC patients found that patients with EGFR ins20 tumors had longer OS and time to treatment cessation with platinum chemotherapy compared with patients without targeted mutations [30]. Here, EGFR is linked to non-small cell lung carcinoma.